Hvivo (HVO)

Sector:

Health Care

Index:

FTSE AIM All-Share

28.50p
   
  • Change Today:
      0.60p
  • 52 Week High: 30.60p
  • 52 Week Low: 18.00p
  • Currency: UK Pounds
  • Shares Issued: 680.37m
  • Volume: 1,724,303
  • Market Cap: £193.91m

Open Orphan makes progress with Covid-19 characterisation study

By Josh White

Date: Thursday 25 Mar 2021

LONDON (ShareCast) - (Sharecast News) - Specialist pharmaceutical services clinical research company Open Orphan updated the market on its world-first Covid-19 characterisation study on Thursday, reporting that the first three volunteers had now completed the quarantine phase.

The AIM-traded firm said that following research ethics committee approval on 17 February, its subsidiary hVIVO began the study at the Royal Free London NHS Foundation Trust in early March.

It said the first three volunteers had successfully completed the quarantine phase of their participation with no safety concerns presented, and had been discharged from the unit.

The study would now progress to the next group of volunteers.

Open Orphan said the first three volunteers would continue their participation with follow-up visits and monitoring for a period of up to one year.

The virus characterisation study would inoculate up to 90 volunteers between the ages of 18 and 30, to enable identification of the most appropriate dose of the virus needed to cause Covid-19 infection in a safe and controlled environment.

It said the study was being funded by the UK Government, with Imperial College London the clinical study sponsor.

The study was being conducted by hVIVO at the Royal Free Hospital, under the scrutiny of "highly-trained" scientists and medics.

Open Orphan said the virus being used in the characterisation study had been produced under hVIVO's supervision by a team at Great Ormond Street Hospital for Children NHS Foundation Trust in London, with support from virologists at Imperial College London.

"We are pleased to announce that the first three volunteers in this world's first study have now successfully completed the quarantine phase - these volunteers will continue to be monitored post-study for up to one year," said hVIVO's chief scientific officer Dr Andrew Catchpole.

"Throughout their stay at the Royal Free Hospital in London, the volunteers are closely monitored by our highly trained team of clinicians.

"We expect that this study will greatly assist our understanding of this disease and provide insights into its progression, natural immune response, and transmission."

At 1511 GMT, shares in Open Orphan were down 1.23% at 32p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Hvivo Market Data

Currency UK Pounds
Share Price 28.50p
Change Today 0.60p
% Change 2.15 %
52 Week High 30.60p
52 Week Low 18.00p
Volume 1,724,303
Shares Issued 680.37m
Market Cap £193.91m

Hvivo Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
95.74% below the market average95.74% below the market average95.74% below the market average95.74% below the market average95.74% below the market average
65.71% below the sector average65.71% below the sector average65.71% below the sector average65.71% below the sector average65.71% below the sector average
Price Trend
78.19% above the market average78.19% above the market average78.19% above the market average78.19% above the market average78.19% above the market average
94.59% above the sector average94.59% above the sector average94.59% above the sector average94.59% above the sector average94.59% above the sector average
Income
94.38% below the market average94.38% below the market average94.38% below the market average94.38% below the market average94.38% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Growth
52.34% above the market average52.34% above the market average52.34% above the market average52.34% above the market average52.34% above the market average
72.22% above the sector average72.22% above the sector average72.22% above the sector average72.22% above the sector average72.22% above the sector average

What The Brokers Say

Strong Buy 3
Buy 3
Neutral 0
Sell 0
Strong Sell 0
Total 6
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Hvivo Dividends

  Latest Previous
  Final Special
Ex-Div 18-Apr-24 04-May-23
Paid 20-May-24 09-Jun-23
Amount 0.20p 0.45p

Trades for 31-Oct-2024

Time Volume / Share Price
16:37 275 @ 28.50p
16:20 71,610 @ 28.25p
16:16 7,150 @ 28.40p
15:56 3,469 @ 28.65p
14:48 150,000 @ 28.15p

Hvivo Key Personnel

CEO Yamin Mo' Khan

Top of Page